| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| BUY | SELL | SELL | BUY | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 7.44▲ | 7.41▲ | 7.48▼ | 7.67▼ | 7.03▲ |
| MA10 | 7.42▲ | 7.48▼ | 7.54▼ | 7.41▲ | 7.41▲ |
| MA20 | 7.40▲ | 7.56▼ | 7.70▼ | 7.08▲ | 10.69▼ |
| MA50 | 7.48▼ | 7.75▼ | 7.48▼ | 7.34▲ | 18.90▼ |
| MA100 | 7.55▼ | 7.44▲ | 7.27▲ | 10.97▼ | 25.12▼ |
| MA200 | 7.71▼ | 7.20▲ | 6.94▲ | 17.39▼ | 38.42▼ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | 0.011▲ | -0.014▼ | -0.055▼ | 0.124▲ | 0.297▲ |
| RSI | 50.171▲ | 39.226▼ | 41.803▼ | 51.513▲ | 31.544▼ |
| STOCH | 86.270▲ | 31.472 | 18.539▼ | 72.372 | 25.899 |
| WILL %R | -18.182▲ | -63.636 | -83.784▼ | -44.828 | -87.729▼ |
| CCI | 109.605▲ | -64.116 | -85.155 | 25.966 | -7.837 |
|
Friday, June 13, 2025 04:00 AM
ARV-393 demonstrated significant single-agent activity in models of nodal T-follicular helper cell lymphoma, angioimmunoblastic-type (also known as AITL) and transformed follicular lymphoma – – In ...
|
|
Friday, June 06, 2025 11:16 AM
Vepdegestrant has been recognized with fast track designation by the FDA and is being co-developed by Arvinas and Pfizer. The recent developments follow the presentation of the VERITAC-2 study at the ...
|
|
Thursday, June 05, 2025 09:00 PM
ARVN), today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) with its partner Pfizer Inc. (NYSE: PFE), for vepdegestrant for the treatment ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 13/06/25 | 7.425 | 7.53 | 7.32 | 7.44 | 256,763 |
| 12/06/25 | 7.61 | 7.85 | 7.46 | 7.57 | 1,146,038 |
| 11/06/25 | 7.88 | 8.06 | 7.6057 | 7.67 | 2,030,886 |
| 10/06/25 | 7.95 | 8.22 | 7.80 | 7.82 | 2,506,541 |
| 09/06/25 | 7.645 | 7.885 | 7.24 | 7.83 | 3,508,888 |
| 06/06/25 | 7.05 | 7.575 | 7.05 | 7.53 | 2,762,860 |
| 05/06/25 | 6.92 | 7.055 | 6.70 | 6.92 | 1,990,174 |
| 04/06/25 | 7.04 | 7.07 | 6.84 | 6.95 | 1,571,091 |
| 03/06/25 | 7.40 | 7.44 | 6.97 | 7.00 | 2,447,295 |
| 02/06/25 | 6.74 | 7.44 | 6.70 | 7.33 | 4,087,842 |
|
|
||||
|
|
||||
|
|